Safe Response Act
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Overview
The Safe Response Act reauthorizes a program that provides grants to government entities to equip first responders with opioid overdose reversal medications like naloxone and offers related training. This bill expands the program’s scope to include training and treatment for overdoses caused by drugs other than opioids, as well as medications and devices legally marketed for use. It also increases the funding available for the program over the next few years. The program is administered by the Substance Abuse and Mental Health Services Administration.
Key provisions
- Reauthorizes the first responder training program through FY2030.
- Expands grant eligibility to include treatment for overdoses from drugs other than opioids.
- Broadens the types of medications and devices covered under the program to include those legally marketed.
- Increases the annual grant funding amount from $36 million to $57 million starting in FY2026.
- Updates language to include ‘Tribes and Tribal’ instead of ‘tribes and tribal’.
Who is affected
- First Responders
- State and Local Government Entities
- Individuals experiencing drug overdoses
- Substance Abuse and Mental Health Services Administration
Notable changes
- The program now covers overdoses from drugs beyond opioids.
- The program now includes legally marketed medications and devices, not just FDA-approved ones.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
3 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours